Petros pharmaceuticals enters into ai licensing agreement with leading multi-billion-dollar software provider

Ai software expected to further enable petros's efforts to make stendra the first ed product to be offered over the counter new york, ny / accesswire / february 14, 2024 / petros pharmaceuticals, inc. (nasdaq:ptpi), a company focused on expanding consumer access to medication through over-the- counter (otc) drug development programs, announces a new partnership with a leading, multi-billion-dollar ai software provider to adapt its technology for self-screening and other benefits as part of the company's ongoing efforts to bring stendra over the counter. the technology will be integrated into the core tool the company has already developed as part of its self-selection study, which is currently underway.
PTPI Ratings Summary
PTPI Quant Ranking